-
VP-16 and Cisplatin Combination Chemotherapy in Small Cell Lung Cancer
-
Jae Seok Kim, Hyuk Chan Kwon, Sung Jin Bae, Myung Hwan Noh, Won Tae Chung, Hyo Jin Kim, Chang Woon Kang, Jong Seong Kim
-
J Korean Cancer Assoc. 1995;27(1):77-84.
-
-
-
 Abstract
 PDF
- Objectives
Despite recent advances in chemotherapy, the treatment outcome of advanced non-small cell lung cancer(NSCLC) remains poor and NSCLC is still the predominant source of cancer-related mortality in worldwide. Thus, we evaluated the efficacy and safety of a combination chemotherapy with mitomycin C, vinblastine, and cisplatin(MVP) in advanced NSCLC patients in Korea. Methods; Cisplatin was infused intravenously at a dose 20 mg/m from 1st to 5th day and mitomycin C 10 mg/m and vinblastine 6 mg/m were given intravenously on day 1. This treatment schedule was repeated every 3 weeks. Results: Among 94 evaluable patients, overall response rate was 44% including 4% of complete response. Squamous cell carcinoma responded better than adenocarcinoma. The median time to progression was 24 weeks and the median survival time was 42 weeks. Statistically significant survival advantage was observed in responder group(60 weeks vs. 36 weeks). The toxicities of this regimen were mild and well tolerated. Conclusion: In advanced NSCLC, MVP combination chemotherapy is relatively effective and safe.
|
KCA
